Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy.

Earle F Burgess¹, Landon Brown¹, Michael McCormack², Liang Liu³, Nury Steuerwald¹, Ericson Stoen², Metamia Ciampricotti⁴, Patrick M Doherty⁵, Edward Williams⁵, Peter Clark⁶, Wei Zhang², James T Symanowski¹

¹Atrium Health Wake Forest Baptist Charlotte, NC United States.

²Atrium Health Wake Forest Baptist Winston-Salem, NC United States.

³Wake Forest University School of Medicine Winston-Salem, NC United States.

⁴Tempus Labs (United States) United States.

⁵Tempus Labs (United States) Chicago, IL United States.

⁶Atrium Health - Wake Forest School of Medicine Charlotte Campus Charlotte, NC United States.

PubMed DOI

Abstract

Pathological complete response (pCR) after neoadjuvant cisplatin-based chemotherapy (NAC) is associated with improved outcomes in muscle-invasive bladder cancer (MIBC), but genomic predictors of benefit remain unvalidated. Based on observations in lung cancer, we hypothesized that MIBC patients with high TMB would be unlikely to benefit from NAC, indicated by residual disease after cystectomy. Pre…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.